Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Merli

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Cancers|January 11, 2022
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III TrialGian Maria Zaccaria, Simone Ferrero, Eva Hoster, et al.
Bone Marrow Transplantation|January 14, 2018
Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) scoreJacopo Olivieri, Immacolata Attolico, Roberta Nuccorini, et al.
Leukemia|November 7, 2025
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trialRiccardo Moia, Simone Ragaini, Luciano Cascione, et al.
Plos One|September 12, 2013
Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patientsLeonardo Potenza, Daniela Vallerini, Patrizia Barozzi, et al.
Bone Marrow Transplantation|July 2, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patientsAttilio Olivieri, Giorgia Mancini, Jacopo Olivieri, et al.
The Lancet. Haematology|October 4, 2016
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort studyClaudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, et al.
Blood Advances|June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphomaAnnalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Cancers|January 11, 2022
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III TrialGian Maria Zaccaria, Simone Ferrero, Eva Hoster, et al.
Bone Marrow Transplantation|January 14, 2018
Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) scoreJacopo Olivieri, Immacolata Attolico, Roberta Nuccorini, et al.
Leukemia|November 7, 2025
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trialRiccardo Moia, Simone Ragaini, Luciano Cascione, et al.
Plos One|September 12, 2013
Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patientsLeonardo Potenza, Daniela Vallerini, Patrizia Barozzi, et al.
Bone Marrow Transplantation|July 2, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patientsAttilio Olivieri, Giorgia Mancini, Jacopo Olivieri, et al.
The Lancet. Haematology|October 4, 2016
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort studyClaudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, et al.
Blood Advances|June 5, 2023
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphomaAnnalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Pageof 16